Moreover, the presence of MGMT promoter methylation in 30% to 50% of IDH wild-type glioblastomas might be indicative of a somewhat improved prognosis and a beneficial reaction to alkylating chemotherapy agents, such as Temozolomide (TMZ) [8]. Here, IDH2 is linked to glioblastoma.